These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24730278)

  • 21. Targeting cancer cells with controlled release nanocapsules based on a single aptamer.
    Hernandez FJ; Hernandez LI; Pinto A; Schäfer T; Özalp VC
    Chem Commun (Camb); 2013 Feb; 49(13):1285-7. PubMed ID: 23295617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.
    Zhu H; Li J; Zhang XB; Ye M; Tan W
    ChemMedChem; 2015 Jan; 10(1):39-45. PubMed ID: 25277749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanocarrier-based approaches for treatment and detection of Alzheimer's disease.
    Oesterling BM; Gulati A; Joshi MD
    J Nanosci Nanotechnol; 2014 Jan; 14(1):137-56. PubMed ID: 24730256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted drug delivery systems for pancreatic cancer.
    Khare V; Alam N; Saneja A; Dubey RD; Gupta PN
    J Biomed Nanotechnol; 2014 Dec; 10(12):3462-82. PubMed ID: 26000366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in Aptamers Targeting Immune System.
    Hu PP
    Inflammation; 2017 Feb; 40(1):295-302. PubMed ID: 27590235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.
    Zhao N; Pei SN; Qi J; Zeng Z; Iyer SP; Lin P; Tung CH; Zu Y
    Biomaterials; 2015 Oct; 67():42-51. PubMed ID: 26204224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenging cancer targets for aptamer delivery.
    de Franciscis V
    Biochimie; 2018 Feb; 145():45-52. PubMed ID: 28962871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment.
    Reinemann C; Strehlitz B
    Swiss Med Wkly; 2014 Jan; 144():w13908. PubMed ID: 24395443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases.
    Kanwar JR; Shankaranarayanan JS; Gurudevan S; Kanwar RK
    Drug Discov Today; 2014 Sep; 19(9):1309-21. PubMed ID: 24598791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection.
    Xiao Z; Levy-Nissenbaum E; Alexis F; Lupták A; Teply BA; Chan JM; Shi J; Digga E; Cheng J; Langer R; Farokhzad OC
    ACS Nano; 2012 Jan; 6(1):696-704. PubMed ID: 22214176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A quantum dot-MUC1 aptamer conjugate for targeted delivery of protoporphyrin IX and specific photokilling of cancer cells through ROS generation.
    Singh S; Jha P; Singh V; Sinha K; Hussain S; Singh MK; Das P
    Integr Biol (Camb); 2016 Oct; 8(10):1040-1048. PubMed ID: 27723851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotechnology and aptamers: applications in drug delivery.
    Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
    Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complex target SELEX.
    Shamah SM; Healy JM; Cload ST
    Acc Chem Res; 2008 Jan; 41(1):130-8. PubMed ID: 18193823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Advances in the study of aptamer-based drug for targeting therapy].
    Dou XQ; Fu J; Song HF
    Yao Xue Xue Bao; 2016 Jul; 51(7):1068-76. PubMed ID: 29897179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
    Luo YL; Shiao YS; Huang YF
    ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-SELEX-based selection of aptamers that recognize distinct targets on metastatic colorectal cancer cells.
    Li WM; Bing T; Wei JY; Chen ZZ; Shangguan DH; Fang J
    Biomaterials; 2014 Aug; 35(25):6998-7007. PubMed ID: 24857291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards targeted cancer therapy: Aptamer or oncolytic virus?
    Tan KX; Danquah MK; Sidhu A; Ongkudon CM; Lau SY
    Eur J Pharm Sci; 2017 Jan; 96():8-19. PubMed ID: 27593990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Process evaluation and in vitro selectivity analysis of aptamer-drug polymeric formulation for targeted pharmaceutical delivery.
    Tan KX; Lau SY; Danquah MK
    Biomed Pharmacother; 2018 May; 101():996-1002. PubMed ID: 29635910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cell-based single-stranded DNA aptamer specifically targets gastric cancer.
    Zhang X; Zhang J; Ma Y; Pei X; Liu Q; Lu B; Jin L; Wang J; Liu J
    Int J Biochem Cell Biol; 2014 Jan; 46():1-8. PubMed ID: 24501772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.